Yibin Kang

USPTO Granted Patents = 7 (Patent Applications = 10)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 2.5

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

Wisconsin Alumni Research Foundation

where one patent can have more than one assignee

Years Active: 2018-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12162855 - Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers (2024-12-10),

2. 12054475 - Substituted heterocycles as aldehyde dehydrogenase inhibitors (2024-08-06),

3. 10786545 - Use of peptides that block metadherin-SND1 interaction as treatment for cancer (2020-09-29),

4. 10745701 - Methods of identifying and treating poor-prognosis cancers (2020-08-18),

5. 10357539 - Use of peptides that block metadherin-SND1 interaction as treatment for cancer (2019-07-23),

6. 10202605 - Methods of identifying and treating poor-prognosis cancers (2019-02-12),

7. 9932587 - Methods of identifying and treating poor prognosis cancers (2018-04-03),

Title: Yibin Kang: Innovator in Cancer Treatment

Introduction

Yibin Kang is a prominent inventor based in Princeton, NJ (US). He has made significant contributions to the field of cancer research, particularly in developing innovative treatments for metastatic and chemoresistant cancers. With a total of 7 patents, his work has the potential to impact the lives of many patients facing these challenging conditions.

Latest Patents

Kang's latest patents include groundbreaking compounds designed to inhibit aldehyde dehydrogenase isoform Ia3 (ALDHIa3). These compounds, known as Tetrahydroquinolino derivatives, are useful for treating various forms of cancer, including those that are resistant to chemotherapy. Additionally, he has developed novel heterocyclic compounds that serve as aldehyde dehydrogenase inhibitors. These compounds have applications in treating not only cancer but also conditions such as type 2 diabetes and pulmonary arterial hypertension.

Career Highlights

Throughout his career, Yibin Kang has been associated with prestigious institutions such as Princeton University and the Wisconsin Alumni Research Foundation. His research has focused on the development of pharmaceutical compositions that can effectively target cancer cells and improve treatment outcomes for patients.

Collaborations

Kang has collaborated with notable colleagues, including Guohong Hu and Yongna Xing, to advance his research and patent applications. Their combined expertise has contributed to the innovative solutions being developed in the field of cancer treatment.

Conclusion

Yibin Kang's work exemplifies the intersection of innovation and healthcare, particularly in the fight against cancer. His patents and research efforts continue to pave the way for new therapeutic options, demonstrating the vital role of inventors in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.